Brown Advisory
INTS icon

Brown Advisory’s Intensity Therapeutics INTS Stock Holding History

Brown Advisory’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,200
Closed -$53.3K – 1428
2025
Q4 		$53.3K Sell
5,200
-3
-0.1% -$30 ﹤0.01% 1374
2025
Q3 		$31.6K Hold
5,203
– – ﹤0.01% 1373
2025
Q2 		$39.9K Hold
5,203
– – ﹤0.01% 1343
2025
Q1 		$256K Hold
5,203
– – ﹤0.01% 1185
2024
Q4 		$229K Sell
5,203
-721
-12% -$52.3K ﹤0.01% 1247
2024
Q3 		$566K Sell
5,924
-377
-6% -$41.9K ﹤0.01% 959
2024
Q2 		$772K Hold
6,301
– – ﹤0.01% 831
2024
Q1 		$819K Buy
+6,301
New +$755K ﹤0.01% 826

Other funds holding INTS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brown Advisory's INTS Position: Q1 2026 in Review

Brown Advisory sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 5,200 shares — an estimated $53.3K sold.

Brown Advisory first reported a position in INTS in Q1 2024 and held it in 8 quarters. The position peaked at $819K in Q1 2024. 13 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Brown Advisory reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brown Advisory sold 5,200 Intensity Therapeutics shares in Q1 2026, an estimated $53.3K.
  • Brown Advisory first reported a position in Intensity Therapeutics in Q1 2024 and held it in 8 quarters.
  • Brown Advisory's Intensity Therapeutics position peaked at $819K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.